近日,炎症性肠病(IBD)领域的创新药企Spyre Therapeutics完成了一次关键资本运作——通过承销公开发行14,864,865股普通股,成功募资约2.75亿美元。这笔由公开市场直接“投票”的资金,为其在长效单抗研发上的激烈竞争提供了关键“弹药”,也清晰地折射出资本市场对这一技术平台的浓厚兴趣。其核心优势在于,能利用多种工程技术显著延长药物在体内的半衰期,将给药频率从数周一次降至数月一次...
Source Link近日,炎症性肠病(IBD)领域的创新药企Spyre Therapeutics完成了一次关键资本运作——通过承销公开发行14,864,865股普通股,成功募资约2.75亿美元。这笔由公开市场直接“投票”的资金,为其在长效单抗研发上的激烈竞争提供了关键“弹药”,也清晰地折射出资本市场对这一技术平台的浓厚兴趣。其核心优势在于,能利用多种工程技术显著延长药物在体内的半衰期,将给药频率从数周一次降至数月一次...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.